Open Heart

DECEMBER 6, 2023

Methods and results A systematic review was performed by searching four main databases (Medline, Embase, SCOPUS, CINAHL) from their inception to 16 June 2022. received ACE inhibitors or aldosterone receptor blockers (ACEIs/ARBs), 54.4% (CI 45.4 53 studies, n=8456 patients (mean 50.1 female) were included.

SCAD 98

SCAD Cardiac Rehabilitation ACE Inhibitor Document 98

DAIC

MARCH 26, 2025

2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Data on file. Bayer Pharmaceuticals. Kerendia (finerenone) [package insert]. Food and Drug Administration. Available at: [link]. Heidenreich P, et al.

Heart Failure 52

Heart Failure Preserved Ejection Fraction Kidney Disease ACE Inhibitor 52

Open Heart

APRIL 24, 2024

Results Data were collected in April 2012 to January 2014 and in June 2021 to December 2022. were on a beta blocker and on an ACE inhibitor/angiotensin receptor blocker/angiotensin receptor-neprilysin inhibitor, respectively. Statistical significance is determined at p<0.05. and 29.2%, p<0.001).

Heart Failure 52

Heart Failure Preserved Ejection Fraction ACE Inhibitor Pharmacology 52

Heart BMJ

MARCH 12, 2024

The aim of this study was to evaluate in a network meta-analysis if beta-blockers (BB) and ACE inhibitors/angiotensin receptor blockers (ACEi/ARBs), in combination or not, can effectively prevent TTS recurrences. We considered all those studies including patients receiving medical therapy with BB, ACEi/ARBs.

ACE Inhibitor 52

ACE Inhibitor Heart Failure Outcomes 52

Open Heart

FEBRUARY 17, 2024

Design A cross-sectional design with self-administered questionnaire with data collected between October 2021 and September 2022. were on ACE inhibitors/angiotensin receptor blockers and 54.9% Confirmation of cases was done through the ejection fraction, medication list and frequent symptoms of the patients. The mean age was 61.3±17.36

Heart Failure 40

Heart Failure Quality of Life ACE Inhibitor COVID-19 40

Dr. Smith's ECG Blog

NOVEMBER 15, 2023

Contemporary research studies of MINOCA have evaluated the prognosis of these patients, reporting a 12-month all-cause mortality of 4.7% (95% confidence interval, 2.6–6.9), 6.9), 3 with comparative studies consistently demonstrating a better prognosis than for those who experience AMI associated with obstructive coronary artery disease.

Coronary Angiogram 109

Coronary Angiogram Plaque Thrombosis STEMI 109

Dr. Smith's ECG Blog

NOVEMBER 30, 2022

J Electrocardiol [Internet] 2022;Available from: [link] Cardiology opinion: Takotsubo Cardiomyopathy (EF 30-35%) V Fib Cardiac arrest Prolonged QTC NSTEMI (Smith comment: is it NSTEMI or is it Takotsubo? -- these are entirely different) Moderate single-vessel CAD. Reference on Troponins: Xenogiannis I, Vemmou E, Nikolakopoulos I, et al.

Plaque 52

Plaque Chest Pain Thrombosis Stenosis 52